Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsKurt Gustafson - Chief Financial OfficerMatt ...

In the assessment of 12-month price targets, analysts unveil insights for AVITA Medical, presenting an average target of $22.0, a high estimate of $25.00, and a low estimate of $14.00. This current ...